Safety and immunogenicity of a heterologous prime-bosst vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults, children and infants in a malaria endemic area.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2016
At a glance
- Drugs ME-TRAP malaria DNA vaccine Okairos (Primary)
- Indications Malaria
- Focus Adverse reactions
- 14 Mar 2012 Planned end date (Mar 2011) added as reported by Pan-African Clinical Trials Registry record.
- 20 Sep 2011 New trial record